The FDA has approved the MEK inhibitor cobimetinib in combination with the BRAF inhibitor vemurafenib for the treatment of advanced metastatic or unresectable BRAF - mutated melanoma. (cancernetwork.com)
The most common adverse events seen with cobimetinib / vemurafenib were diarrhea, photosensitivity reaction, nausea, pyrexia, and vomiting. (cancernetwork.com)
People taking cobimetinib should avoid sun exposure, wear protective clothing, and a broad spectrum ultraviolet A / ultraviolet B sunscreen to protect against sunburn. (cancernetwork.com)